<DOC>
	<DOCNO>NCT00405015</DOCNO>
	<brief_summary>Cardiovascular disease lead cause death diabetic patient due high event rate bad outcome . A pharmacological intervention reduces ischemia-reperfusion-injury would improve outcome diabetic patient cardiovascular event . In present study , use annexinA5 scintigraphy address follow hypothesis : Rosiglitazone reduce ischemia-reperfusion-injury human insulin resistance .</brief_summary>
	<brief_title>The Effect Rosiglitazone Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy .</brief_title>
	<detailed_description>Rationale : Cardiovascular disease lead cause death diabetic patient due high event rate bad outcome . A pharmacological intervention reduces ischemia-reperfusion-injury would improve outcome diabetic patient cardiovascular event . The thiazolidinedione derivatives peroxisome proliferator-activated receptor-γ ( PPARγ ) ligands approved treatment hyperglycemia type 2 diabetes mellitus . Animal data suggest PPARγ ligand protect ischemia-reperfusion-injury improving insulin responsiveness . However , human data beneficial effect available . Recently , group develop human vivo model quantify ischemia-reperfusion-injury . In model annexin A5 scintigraphy use visualize early reversible cellular membrane change occur forearm skeletal muscle vascular bed ischemic exercise . In present study , use approach address follow hypothesis : Rosiglitazone reduce ischemia-reperfusion-injury human insulin resistance , select use criterion metabolic syndrome . Study design : This single-center randomized , double blind , placebo-controlled crossover study washout period 6 week . Study population : Men postmenopausal woman , age 20-70 year metabolic syndrome . Intervention : Every subject use 8 week rosiglitazone 4 mg bd placebo bd . Week 8 22 : assessment ischemic-reperfusion injury Technetium Annexin A5 Scintigraphy . Ischemic intervention : 10 minute ischemia non-dominant arm time rhythmic contraction forearm hand muscle . Main study parameters/endpoints : Annexin target thenar muscle ischemic exercise . The primary analysis difference annexin target follow 8 week treatment rosiglitazone 4 mg bd placebo .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Annexin A5</mesh_term>
	<criteria>At least 3 feature metabolic syndrome ( AHA/NHLBI ) . Willing able provide sign dated write informed consent . Men postmenopausal woman age 20 70 year . Fasting glucose &gt; 7,0 mmol/L use hypoglycaemic agent . If fasting plasma glucose 6.1 7,0 mmol/L , oral 75 g glucose test perform exclude diabetes mellitus . Exposure PPARg agonist last 4 month document significant hypersensitivity PPARg agonist . Participant another study . Angina heart failure ( NYHA IIV ) . Clinically significant liver disease ( 3 time upper normal limit ALAT , ASAT , AF , γGT LDH ) Clinically significant anemia ( male Hb &lt; 6,9 mmol/L , female &lt; 6,25 mmol/L ) Creatinin clearance &lt; 40 mL/min Alcohol drug abuse . Any physical inability perform exercise protocol . Administration radio pharmacon research purpose previous 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>rosiglitazone</keyword>
	<keyword>ischemia-reperfusion injury</keyword>
	<keyword>human</keyword>
	<keyword>Annexin A5 scintigraphy</keyword>
	<keyword>metabolic syndrome</keyword>
</DOC>